Double-Blind Naltrexone in Compulsive Sexual Behavior

Compulsive Sexual Behavior Clinical Trial

Official title: A Double-Blind, Placebo-Controlled Study of Naltrexone in Compulsive Sexual Behavior

Status Completed

Clinical Trial Summary

The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in compulsive sexual behavior. Twenty subjects with DSM-IV compulsive sexual behavior will receive 8 weeks of naltrexone or placebo. The hypothesis to be tested is that naltrexone will be effective in reducing the urges to act out sexually in patients with compulsive sexual behavior. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Clinical Trial Description

The proposed study will consist of 8 weeks of treatment with either naltrexone or placebo in 20 subjects with compulsive sexual behavior. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Compulsive Sexual Behavior

• NCT number: NCT00467558
• Study type: Interventional
• Source: University of Minnesota - Clinical and Translational Science Institute
• Status: Completed
• Phase: Phase 2
• Start date: May 2007
• Completion date: June 2010